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Abstract
A systematic review and meta-analysis were performed to determine and compare the sensitivity and speciﬁcity of PCR-based and cul-
ture-based diagnostic tests for methicillin-resistant Staphylococcus aureus (MRSA). Our analysis included 74 accuracy measurements from
29 publications. Nine tests were evaluated: the PCR-based Genotype MRSA Direct and IDI-MRSA, the chromogenic media CHROMa-
gar, Chromogenic MRSA Medium, MRSA ID, MRSA Select and ORSAB, and the nonchromogenic culture media MSA-Cefoxitin and
MSA-Oxacillin. For four chromogenic media, incubation periods of 18–24 and 48 h were evaluated. Considerable heterogeneity was
detected in most analyses. A signiﬁcantly higher sensitivity was found for the overall PCR pooled estimate (92.5; 95% CI 87.4–95.9) and
the chromogenic media after 48 h of incubation (87.6; 95% CI 82.1–91.6) compared to the overall sensitivity of chromogenic media
after 18–24 h (78.3; 95% CI 71.0–84.1). The speciﬁcity of chromogenic media after 18–24 h (98.6; 95% CI 97.7–99.1) was higher than
the speciﬁcity of PCR (97.0; 95% CI 94.5–98.4) but declined after 48 h of incubation (94.7; 95% CI 91.6–96.8).The most sensitive chro-
mogenic medium after 18–24 h of incubation was Chromogenic MRSA Medium (sensitivity: 89.3; 95% CI 72.8–96.3), whereas the most
speciﬁc chromogenic medium after 18–24 h of incubation was MRSA Select (speciﬁcity: 99.4; 95% CI 98.6–99.7). After 48 h of incuba-
tion, MRSA Select had the highest sensitivity (93.2; 95% CI 83.5–97.0), whereas CHROMagar had the highest speciﬁcity (96.4; 95% CI
91.3–98.5). This meta-analysis showed statistically signiﬁcant differences in diagnostic accuracy between several of the tests and the test
methods evaluated. A reduction of the incubation time of chromogenic media (from 48 to 18–24 h) increases speciﬁcity but reduces
sensitivity.
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Introduction
Staphylococcus aureus is one of the most common causes of
nosocomial and community-acquired infections. The ﬁrst
methicillin-resistant Staphylococcus aureus (MRSA) strain was
detected in 1960 [1], 1 year after the introduction of methi-
cillin in 1959. Methicillin resistance is mediated by the peni-
cillin-binding protein 2a (PBP-2a), a variant of the PBP-2
protein, encoded in the mecA gene. Ever since the 1980s,
incidences of infections caused by MRSA as well as asymp-
tomatic carriage by hospitalized patients, have increased dra-
matically worldwide [2–4]. Carriage of MRSA is an important
risk factor for subsequent infection, with the anterior nares
being the primary predilection site [5].
Although proportions of nosocomial MRSA infections
among all S. aureus infections have reached high levels in
many countries, a number of countries, such as the Nether-
lands and the Scandinavian countries [4], have maintained
low prevalence rates with stringent infection control policies.
These policies consist of a combination of measures, such as
isolation of identiﬁed MRSA carriers, decolonizing patients,
admission screening of high-risk patients with pre-emptive
isolation, screening of all contact patients and health care
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workers (HCW) and unexpected (index) cases, furloughing
of HCWs from work and closing of wards in case of
uncontrolled spread. Bootsma et al. [6] recently investigated
the individual contribution of the components of this Dutch
search and destroy policy [7], indicating that admission screen-
ing of high-risk patients in combination with (pre-emptive)
isolation could be highly beneﬁcial, even in high-prevalence
settings. When performing such a strategy, rapid detection is
crucial, limiting transmission risks and the costs of isolation.
Conventional microbiological cultures have a diagnostic delay
of at least 48 h, which increases when broth enrichment of
material is used. Several novel and faster diagnostic tests to
screen for MRSA have been introduced in the last 5 years.
To select an appropriate test for a hospital admission
screening programme, one also needs to consider a test’s
speciﬁcity, sensitivity and price, in addition to the turnaround
time (TAT). Obviously, false positive results will drive up iso-
lation costs, whereas false negative results will increase the
risks of transmission but, on closer examination, the inter-
play of the test characteristics with the local conditions
within different screening strategies becomes quite complex.
Mathematical modelling studies can inform hospital decision-
makers on cost-effective combinations of tests and screening
strategies within a particular setting, although such studies
require accurate estimates of diagnostic accuracy.
The present study aimed to determine and compare the
sensitivity and speciﬁcity of nine commercially available diag-
nostic MRSA tests using systematic review and meta-analysis
techniques in line with the PRISMA guidelines [8], including:
the PCR-based Genotype MRSA Direct and IDI-MRSA,
CHROMagar, Chromogenic MRSA Medium, MRSA ID, MRSA
Select, ORSAB, MSA-Cefoxitin and MSA-Oxacillin.
Materials and Methods
Search strategy
A literature search of Medline and Embase was conducted to
identify publications that were published before or during
2008. Keywords and Boolean operators used for searches
were ‘MRSA’ OR (‘resistant’ AND ‘Staphylococcus aureus’)
AND ‘detection’ AND (‘sensitivity’ OR ‘speciﬁcity’). No
restrictions were set for language or publication type. The
reference lists of enrolled publications were reviewed until
no further new publications were identiﬁed.
Inclusion criteria
Nine different commercially available screening tests were
assessed with incubation times £48 h: two PCR-based tests,
IDI-MRSA (BD Diagnostics, Sparks, MD, USA) and Genotype
MRSA direct (HAIN Lifescience, Nehren, Germany), ﬁve
chromogenic media, CHROMagar (BD Diagnostics; and
CHROMagar Microbiology, Paris), Chromogenic MRSA Med-
ium (Oxoid, Hampshire, UK), MRSA ID (BioMe´rieux, La-Bal-
mes-les-Grottes, France), MRSA Select (Bio-Rad, Marnes-la-
Coquette, France) and ORSAB (Oxoid, Hampshire, UK) and
two nonchromogenic culture media, MSA-Cefoxitin and
MSA-Oxacillin (various sources).
Titles and abstracts of all publications were read by two
reviewers (GAAH and JML). The full text was obtained if the
abstract suggested a diagnostic accuracy study of one or
more PCR-based or culture-based MRSA tests. Publications
were eligible for inclusion if: (i) the results were reported as
true negative (TN), true positive (TP), false positive (FP) and
false negative (FN) on screened sample level, or if these out-
comes were derivable from the presented data; (ii) more than
80% of the screened samples consisted of axilla, groin, nose,
perineum and throat samples; and (iii) if samples were not
taken from a strain library. The latter two restrictions were
set to reduce heterogeneity and to exclude samples that
were not representative of samples obtained through hospital
admission screening. No restrictions were set for the clinical
reference standard method applied.
Validity assessment
Quality assessment of included publications was performed
using the QUADAS tool [9]. Because the QUADAS tool
does not incorporate a quality score for various reasons, no
regression analysis was performed on publication quality and
diagnostic performance of tests evaluated and no publications
were excluded based on quality assessment.
Ethical considerations
This study did not require the approval of an ethics commit-
tee.
Data extraction
Data were extracted from each included publication by review-
ers JML and GAAH and included TN, TP, FP and FN. Data were
collected in 2 · 2 tables and subsequently pooled by test and
category (PCR-based, chromogenic and nonchromogenic
culture media). The ﬁve chromogenic agar-based tests were
further subcategorized according to incubation times of 18–
24 h and 48 h. Subgroups were created for nasal swabs and
manufacturer (CHROMagar; BD Diagnostics and CHROMagar
Microbiology) if three or more publications were available.
Quantitative data synthesis
The statistical analysis was carried out using R, version 2.8.1
[10] and SAS software [11]. The hypothesis of inter-study
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heterogeneity was statistically tested using the i-squared sta-
tistic [12]. Values of i-squared equal to 25%, 50% and 75%
were considered to represent low, moderate and high levels
of heterogeneity, respectively. We further investigated the
causes of heterogeneity by means of subgroup analyses.
Pooled sensitivity, speciﬁcity and 95% conﬁdence intervals
were estimated for each test using the bivariate method
described by Reitsma et al. [13]. Using this method, we were
also able to perform pairwise investigations of differences
between the sensitivity and speciﬁcity of all main pools. p
<0.05 was considered statistically signiﬁcant.
To assess publication bias, we used the relation between
the diagnostic odds ratio (DOR) and the effective sample
size (ESS) [14]. In particular, a regression of the natural loga-
rithm of DOR against 1/ESS1/2, weighted by ESS was per-
formed. p <0.05 was considered statistically signiﬁcant.
Results
Selection ﬂow
We identiﬁed 599 publications, of which 28 met our inclu-
sion criteria [15–42]. One additional eligible publication [43]
was detected through the reference list of an enrolled publi-
cation (Fig. 1). The 29 enrolled publications (Table 1) yielded
a total of 90 accuracy measurements, of which 16 did not
include nor allow derivation of TN and FP. Because our sta-
tistical methodology requires both sensitivity and speciﬁcity
estimates, those 16 comparisons were excluded.
Study characteristics
The number of accuracy measurements included in the main
pools was 15 for PCR-based, 28 for chromogenic 18–24 h, 24
for chromogenic 48 h and seven for nonchromogenic 48-h
culture tests (Table 2). Our subgroup analysis on nasal swabs
included a total of 25 accuracy measurements. The average
number of samples in the selected accuracy measurements
included was 936 (95% CI 0–2215) and the average number
of MRSA-positive samples (TP + FN) was 92 (95% CI 36–
147). The most commonly encountered shortcomings identi-
ﬁed by the QUADAS tool were failure to blind reference test
readers to results of the index test (n = 29), partial veriﬁca-
tion bias (n = 27) and differential veriﬁcation bias (n = 23).
The most commonly used reference standards were suscepti-
bility testing with agar diffusion (n = 13), mecA PCR (n = 15)
and latex agglutination of PBP2a (n = 9) (Table 1).
Quantitative data synthesis
The overall pooled estimates of the test sensitivities and
speciﬁcities are shown in Table 2. Receiver-operating char-
acteristic plots including the individual accuracy measure-
ments grouped per diagnostic test are shown in Figs 2, 3
and 4. Bivariate summary estimates of sensitivity and
speciﬁcity and 95% conﬁdence ellipses of each of the
evaluated diagnostic tests are graphically represented in
Figs 5, 6 and 7.
Comparing test methods, a signiﬁcantly higher sensitivity
was found for the overall PCR pooled estimate (92.5; 95%
CI 87.4–95.9) compared to the overall estimate of chromo-
genic media after 18–24 h (78.3; 95% CI 71.0–84.1) and 48 h
of incubation (87.6; 95% CI 82.1–91.6). The speciﬁcity of
chromogenic media after 18–24 h (98.6; 95% CI 97.7–99.1)
is higher than the speciﬁcity of PCR (97.0; 95% CI 94.5–98.4)
but declines after 48 h of incubation (94.7; 95% CI 91.6–
96.8). Culture-based tests showed sensitivity comparable
with other test methods evaluated but performed worse
with respect to speciﬁcity.
Among PCR-based tests, the sensitivity of IDI MRSA was
higher than that of Genotype MRSA, although the speciﬁci-
ties of these two tests were comparable.
Among the chromogenic media after 18–24 h of incuba-
tion, Chromogenic MRSA Medium had the highest sensitivity
(89.3; 95% CI 72.8–96.3), whereas MRSA Select had the
highest speciﬁcity (99.4; 95% CI 98.6–99.7) (not signiﬁcant).
Among the chromogenic media after 48 h of incubation,
MRSA Select had the highest sensitivity (93.2; 95% CI 83.5–
97.0), whereas CHROMagar had the highest speciﬁcity (96.4;
95% CI 91.3–98.5) (not signiﬁcant).
The vast majority of the 44 data pools evaluated was
found to be moderately (n = 5), or highly heterogeneous
599 potentially 
relevant articles 
identified by database 
search
34 potentially relevant articles 
identified by reference tracking
598 unique articles
–6 duplicates in 
database
–29 tracked articles 
identified in database
598 unique articles 
screened
518 articles excluded
–381 no diagnostic accuracy study
–137 No MRSA screening test or 
test did not satisfy inclusion criteria
80 articles selected for 
full review
51 articles excluded
–27 strain library used
–9 blood cultures used
–6 screening site unknown
5 screening site did not satisfy 
inclusion criteria
–3 community acquired MRSA
–1 non-derivable results29 articles included in 
study
FIG. 1. Flow chart of the article selection process.
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(n = 39). Sufﬁcient data were available for subgroup analysis
concerning nasal swabs for IDI-MRSA, CHROMagar and
MRSA Select. Comparison of nasal swab-only data to com-
plete data (including samples from other body sites) revealed
nonsigniﬁcant differences for IDI-MRSA, CHROMagar and
MRSA Select (Table 2). In general, sensitivity was slightly
higher for nasal swabs only, whereas the speciﬁcity hardly
changed. No signiﬁcant differences were obtained for sub-
group analysis of CHROMagar manufacturer (data not
shown). No publication bias was discovered in the data pools
of individual tests.
Discussion
This meta-analysis provides an overview of the diagnostic
accuracy of MRSA screening tests reported in the literature
and can be used to compare individual tests as well as testing
methods.
The reduction in sensitivity estimates of the oxacillin-
containing ORSAB chromogenic medium from 82.9% to
67.4%, when shortening incubation time from 48 to 18–
24 h, might be caused by delayed oxacillin resistance
expression [16]. The low performance of MSA-Oxacillin in
terms of sensitivity might be caused by some MRSA
strains that could become inhibited by the salt component
of mannitol salt agar [44].
The analyses including swabs from different body sites
showed a slightly (but not signiﬁcantly) lower sensitivity and
similar speciﬁcity for IDI-MRSA, CHROMagar and MRSA
Select, compared to the analyses of nasal swabs only. This
decreased sensitivity might be caused by a larger amount of
competing ﬂora or a result of lower levels of MRSA coloni-
zation at these anatomical sites [45]. This suggests that these
tests can be used safely for screening of body sites other
than the nares.
The most important limitation of the present study was
the high level of heterogeneity of most study pools. There-
fore, our estimates should be interpreted with caution. Likely
causes of this heterogeneity are the differences between
studies in the design (reference method, test protocol, deﬁ-
nition of a positive result), the geographical location (diverse
MRSA prevalence, local strain dominance) and the incubation
time (a range of 18–24 h for chromogenic media). The
causes of heterogeneity were investigated by subgroup analy-
sis, although the level of information provided by the
included studies was not sufﬁcient for extensive subgroup
analysis. We performed subgroup analysis by nasal swabs and
by manufacturer, but this did not allow us to further explain
the causes of heterogeneity.T
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This meta-analysis was based on indirect, unpaired accu-
racy measurements and did not take advantage of the
strengths of several studies that included head-to-head com-
parisons of MRSA tests in a single series of patients. Pooling
by head-to-head comparisons would have probably reduced
heterogeneity but also pool sizes.
TABLE 2. Pooled estimates of sensitivity and speciﬁcity with 95% conﬁdence intervals
Screening strategy Number of studies
Effective sample
size regression
test (p value) Sensitivity (95% CI) Speciﬁcity (95% CI)
PCR 15 – 92.5% (87.4–95.9) 97.0% (94.5–98.4)
Genotype MRSA 2 NA 83.8% (53.9–95.8) 97.7% (88.3–99.6)
IDI-MRSA 13 0.36 93.8% (88.7–96.6) 96.9% (94.2–98.4)a
IDI-MRSA Nasal 11 0.37 94.8% (90.0–97.4) 96.7% (92.9–98.5)
Chromogenic, 18–24 h 28 – 78.3% (71.0–84.1)b,c 98.6% (97.7–99.1)
CHROMagar 6 0.10 80.3% (64.5–90.2)d,e 99.0% (97.2–99.7)
CHROMagar Nasal 4 0.21 86.4% (71.4–94.2) 99.1% (96.5–99.8)
Chromogenic MRSA Medium 3 0.90 89.3% (72.8–96.3) 98.5% (94.4–99.6)
MRSA ID 4 0.11 65.1% (41.3–83.2)d,e,f,g,h 98.2% (93.4–99.5)
MRSA Select 9 0.13 83.2 % (71.7–90.6)d 99.4% (98.6–99.7)
MRSA Select Nasal 3 0.18 88.4% (73.7–96.1) 99.5% (97.2–99.9)
ORSAB 6 0.47 67.4% (48.3–82.0)d,e,f,g,h 95.0% (87.9–98.1)a,i
Chromogenic, 48 h 24 – 87.6% (82.1–91.6) 94.7% (91.6–96.8)j
CHROMagar 7 0.10 88.1% (77.4–94.1) 96.4% (91.3–98.5)a
CHROMagar Nasal 4 0.27 93.8% (84.8–97.6) 96.0% (85.6–99.0)
MRSA ID 4 0.10 83.1% (64.5–93.0) 92.9% (80.1–97.7)a,i
MRSA Select 6 0.10 93.2% (83.5–97.0) 96.2% (90.4–98.5)a
MRSA Select Nasal 3 0.15 94.1% (82.5–98.2) 93.8% (76.3–98.6)
ORSAB 7 0.43 82.9% (69.5–91.2)d 91.8% (82.4–96.4)a,f,i
Culture, 48 h 7 – 86.9% (74.7–93.7) 89.7% (77.7–95.6)b,j
MSA-Cefoxitin 2 NA 95.5% (81.4–99.0) 81.4% (46.6–95.6)a,d,f,i,k
MSA-Oxacillin 5 0.24 81.7% (64.3–91.8)d 92.1% (80.4–97.1)f,i,a
The bivariate method described in detail by Reitsma et al. [13] was used to calculate and compare diagnostic accuracy estimates. NA, not available. Main pools are
emphasized in bold
aSigniﬁcantly lower than MRSA Select 18–24 h.
bSigniﬁcantly lower than the PCR-group.
cSigniﬁcantly lower than the 48 h chromogenic group.
dSigniﬁcantly lower than IDI-MRSA.
eSigniﬁcantly lower than MRSA Select 48 h.
fSigniﬁcantly lower than Chromogenic MRSA Medium 18–24 h.
gSigniﬁcantly lower than CHROMagar 48 h.
hSigniﬁcantly lower than MSA-Cefoxitin 48 h.
iSigniﬁcantly lower than CHROMagar 18–24 h.
jSigniﬁcantly lower than the 18–24 h chromogenic group.
kSigniﬁcantly lower than MRSA ID 18–24 h.
= Chromagar 18–24 h
= Chromogenic MRSA medium 18–24 h
= MRSA ID 18–24 h
= MRSA select 18–24 h
= ORSAB 18–24 h
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FIG. 3. Receiver-operating characteristic plot of sensitivity against
1 – speciﬁcity for the 28 18–24 h chromogenic media test compari-
sons included in this meta-analysis.
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FIG. 2. Receiver-operating characteristic plot of sensitivity against
1 – speciﬁcity for the 15 PCR comparisons included in this meta-
analysis.
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The database keyword search may not have been optimal
[46], but any missed articles are likely to have been detected
through reference tracking.
In addition to diagnostic accuracy, the TAT of a test is
important in a screening programme but was outside the
scope of this study. A minority of studies included in our
analysis reported on TAT, but often not based on an appro-
priate study design and not generalizable to clinical practice.
Future studies on diagnostic accuracy should consider incor-
porating measurement of TAT in clinical practice. The choice
of a test will also depend on its price. A cost-effectiveness
analysis using mathematical modelling can inform decision-
makers on the interaction and trade-offs between price, sen-
sitivity, speciﬁcity and TAT within different screening strate-
gies.
In conclusion, this meta-analysis showed statistically signiﬁ-
cant differences in diagnostic accuracy between several tests
evaluated. A reduction of the incubation time on chromo-
genic media, from 48 to 18–24 h, increases speciﬁcity, but
reduces sensitivity. Inclusion of non-nasal samples slightly
= Chromagar 48 h
= MRSA ID 48 h
= MRSA select 48 h
= ORSAB 48 h
= MSA-Cefoxitin 48 h
= MSA-Oxacillin 48 h
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FIG. 4. Receiver-operating characteristic plot of sensitivity against
1 – speciﬁcity for the 31 48 h culture (both chromogenic and non-
chromogenic) test comparisons included in this meta-analysis.
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FIG. 5. Bivariate summary estimates of sensitivity and speciﬁcity for
both PCR tests evaluated and the 95% conﬁdence ellipses around
these mean values.
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FIG. 6. Bivariate summary estimates of sensitivity and speciﬁcity for
all ﬁve 18–24-h chromogenic media tests evaluated and the 95%
conﬁdence ellipses around these mean values.
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FIG. 7. Bivariate summary estimates of sensitivity and speciﬁcity for
all six 48-h culture (both chromogenic and nonchromogenic) tests
evaluated and the 95% conﬁdence ellipses around these mean values.
To improve readability, the conﬁdence ellipse of MSA-Cefoxitin 48 h
(in light-blue) is not fully covered.
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(although nonsigniﬁcantly) reduced sensitivity, but did not
change speciﬁcity.
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